Intratumor heterogeneity, which fosters tumor evolution, is a key challenge in cancer
medicine. Here, we review data and technologies that have revealed intra-tumor …

A fundamental prerequisite for the efficacy of cancer immunotherapy is the presence of
functional, antigen-specific T cells within the tumor. Neoantigen-directed therapy is a …

Subclonal reconstruction from bulk tumor DNA sequencing has become a pillar of cancer
evolution studies, providing insight into the clonality and relative ordering of mutations and …

Intra-tumor heterogeneity (ITH) is a mechanism of therapeutic resistance and therefore an
important clinical challenge. However, the extent, origin, and drivers of ITH across cancer …

Distilling biologically meaningful information from cancer genome sequencing data requires
comprehensive identification of somatic alterations using rigorous computational methods …

Accurate measurement of clonal genotypes, mutational processes, and replication states
from individual tumor-cell genomes will facilitate improved understanding of tumor evolution …

Single-cell barcoding technologies enable genome sequencing of thousands of individual
cells in parallel, but with extremely low sequencing coverage (< 0.05×) per cell. While the …

The sequencing of cancer genomes may enable tailoring of therapeutics to the underlying
biological abnormalities driving a particular patient's tumor. However, sequencing-based …

Our understanding of cancer is being transformed by exploring clonal diversity, drug
resistance, and causation within an evolutionary framework. The therapeutic resilience of …

Tumors often contain multiple subpopulations of cancerous cells defined by distinct somatic
mutations. We describe a new method, PhyloWGS, which can be applied to whole-genome …